ascopubs.org

Journal of Clinical Oncology Podcast

The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.
Nasdaq

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) ...
Business Wire

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced positive final results from the Phase 2 TELLOMAK study in Sézary ...
Medical Xpress

Study finds S. aureus can offset the effect of cancer therapy for Sezáry syndrome

The bacteria Staphylococcus aureus (S. aureus) can worsen the condition of patients with the lymphoma type Sezáry syndrome. A Danish research team has found an underlying mechanism. The improved ...
ascopubs.org

Racial differences in survival and prognostic factors among patients with mycosis fungoides and Sézary syndrome: A systematic review and meta-analysis.

An APP-led intake model to expedite diagnostic workup for patients with suspected lymphoma. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full ...

New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome

Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers ...